Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity
AssigneeNorthwestern University
InventorPaul W. Burridge
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, pharmaceutical compositions, kits, and systems for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent. The methods, pharmaceutical compositions, kits, and systems typically include or utilize an agonist of the retinoic acid receptor gamma (RARG).
Claims19
A method for treating or preventing cardiotoxicity in a subject undergoing treatment with an anthracycline chemotherapeutic agent, the method comprising administering to the subject an agonist of the retinoic acid receptor gamma (RARG).
A pharmaceutical composition comprising a combination of an anthracycline chemotherapeutic agent and an agonist of the retinoic acid receptor gamma (RARG).
A kit or treatment system comprising as components an anthracycline chemotherapeutic agent and an agonist of the retinoic acid receptor gamma (RARG).
Dependencies are inferred from the claim text.